Literature DB >> 15035789

Place of OTC analgesics and NSAIDs in osteoarthritis.

Nicholas Moore1.   

Abstract

The risk related to the use of non-steroid anti-inflammatory drugs (NSAIDs) depends on the dose and duration of their use, in addition to the nature of the drug, and patient characteristics. The measures of risk and recent promotion of safer drugs have been mostly based on the results of clinical trials using continuous full-dose use of NSAIDs for periods up to 12 months which may not reflect real-life use and risks of the drugs. To assess this we did two studies of the utilisation of NSAIDs, one in a claims database to measure the amount of drugs dispensed to OA patients over 9 months, which showed that only a small fraction of patients actually bought enough analgesics or NSAIDs to cover the whole study period. On average, patients bought enough NSAIDs to cover 60 of 270 days. The second study was a survey of General Practitioners and rheumatologists to assess the number of users of NSAIDs seen over 2 days' consultations, the indications for and patterns of NSAIDs use. 11% of GP patients and 26% of rheumatologists' patients used NSAIDs, one-third for osteoarthritis (OA), about 8-10% for rheumatoid arthritis (RA) and the rest for various painful conditions. In OA and other conditions patients, more than 70% of patients had been taking their NSAIDs for less than 15 days at the time of consultation, whereas 42% of RA patients had been taking them for more than 6 months.

Entities:  

Year:  2003        PMID: 15035789     DOI: 10.1163/156856003322699537

Source DB:  PubMed          Journal:  Inflammopharmacology        ISSN: 0925-4692            Impact factor:   4.473


  7 in total

1.  Comment on 'Quantitative estimation of rare adverse events which follow a biological progression: a new model applied to chronic NSAID use' Tramer et al., Pain 2000;85:169-182.

Authors:  Nicholas Moore
Journal:  Pain       Date:  2001-04       Impact factor: 6.961

2.  Comparison of an antiinflammatory dose of ibuprofen, an analgesic dose of ibuprofen, and acetaminophen in the treatment of patients with osteoarthritis of the knee.

Authors:  J D Bradley; K D Brandt; B P Katz; L A Kalasinski; S I Ryan
Journal:  N Engl J Med       Date:  1991-07-11       Impact factor: 91.245

3.  Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.

Authors:  F E Silverstein; G Faich; J L Goldstein; L S Simon; T Pincus; A Whelton; R Makuch; G Eisen; N M Agrawal; W F Stenson; A M Burr; W W Zhao; J D Kent; J B Lefkowith; K M Verburg; G S Geis
Journal:  JAMA       Date:  2000-09-13       Impact factor: 56.272

4.  Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group.

Authors:  C Bombardier; L Laine; A Reicin; D Shapiro; R Burgos-Vargas; B Davis; R Day; M B Ferraz; C J Hawkey; M C Hochberg; T K Kvien; T J Schnitzer
Journal:  N Engl J Med       Date:  2000-11-23       Impact factor: 91.245

5.  Quantitative estimation of rare adverse events which follow a biological progression: a new model applied to chronic NSAID use.

Authors:  M R Tramèr; R A Moore; D J Reynolds; H J McQuay
Journal:  Pain       Date:  2000-03       Impact factor: 6.961

6.  Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis.

Authors:  D Henry; L L Lim; L A Garcia Rodriguez; S Perez Gutthann; J L Carson; M Griffin; R Savage; R Logan; Y Moride; C Hawkey; S Hill; J T Fries
Journal:  BMJ       Date:  1996-06-22

7.  Inhibition of clinical benefits of aspirin on first myocardial infarction by nonsteroidal antiinflammatory drugs.

Authors:  Tobias Kurth; Robert J Glynn; Alexander M Walker; K Arnold Chan; Julie E Buring; Charles H Hennekens; J Michael Gaziano
Journal:  Circulation       Date:  2003-08-25       Impact factor: 29.690

  7 in total
  7 in total

1.  Usage patterns of 'over-the-counter' vs. prescription-strength nonsteroidal anti-inflammatory drugs in France.

Authors:  Mai Duong; Francesco Salvo; Antoine Pariente; Abdelilah Abouelfath; Regis Lassalle; Cecile Droz; Patrick Blin; Nicholas Moore
Journal:  Br J Clin Pharmacol       Date:  2014-05       Impact factor: 4.335

2.  Coronary Events After Dispensing of Ibuprofen: A Propensity Score-Matched Cohort Study Versus Paracetamol in the French Nationwide Claims Database Sample.

Authors:  Mai Duong; Abdelilah Abouelfath; Regis Lassalle; Cécile Droz; Patrick Blin; Nicholas Moore
Journal:  Drug Saf       Date:  2018-11       Impact factor: 5.606

3.  Are traditional NSAIDs prescribed appropriately among French elderly with osteoarthritis? Results from the CADEUS cohort.

Authors:  Sinem Ezgi Gulmez; Cécile Droz-Perroteau; Régis Lassalle; Patrick Blin; Bernard Bégaud; Michel Rossignol; Nicholas Moore; Annie Fourrier-Réglat
Journal:  Eur J Clin Pharmacol       Date:  2011-03-09       Impact factor: 2.953

4.  Usage patterns of paracetamol in France.

Authors:  Mai Duong; Sinem Ezgi Gulmez; Francesco Salvo; Abdelilah Abouelfath; Régis Lassalle; Cécile Droz; Patrick Blin; Nicholas Moore
Journal:  Br J Clin Pharmacol       Date:  2016-05-18       Impact factor: 4.335

5.  Hospitalizations for gastrointestinal and cardiovascular events in the CADEUS cohort of traditional or Coxib NSAID users.

Authors:  David Laharie; Cécile Droz-Perroteau; Jacques Bénichou; Michel Amouretti; Patrick Blin; Bernard Bégaud; Estelle Guiard; Sylvie Dutoit; Stéphanie Lamarque; Yola Moride; Fanny Depont; Annie Fourrier-Réglat; Nicholas Moore
Journal:  Br J Clin Pharmacol       Date:  2010-03       Impact factor: 4.335

Review 6.  Non-steroidal anti-inflammatory drug use in chronic pain conditions with special emphasis on the elderly and patients with relevant comorbidities: management and mitigation of risks and adverse effects.

Authors:  Martin Wehling
Journal:  Eur J Clin Pharmacol       Date:  2014-08-28       Impact factor: 2.953

7.  Phytalgic, a food supplement, vs placebo in patients with osteoarthritis of the knee or hip: a randomised double-blind placebo-controlled clinical trial.

Authors:  Alain Jacquet; Pierre-Olivier Girodet; Antoine Pariente; Karelle Forest; Laurent Mallet; Nicholas Moore
Journal:  Arthritis Res Ther       Date:  2009-12-16       Impact factor: 5.156

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.